Abstract:Background: TBX1 is a member of the T-box family of transcription factors characterized by a conserved DNA binding domain termed T-box. TBX1 has been reported to be downregulated in mouse skin tumors and is considered a negative regulator of tumor cell growth in mice. However, its role and exact mechanism in human cancers, including thyroid cancer, remain totally unknown. Methods: Quantitative reverse transcription polymerase chain reaction and Western blot assays were performed to evaluate the expression of investigated genes. Methylation-specific polymerase chain reaction and pyrosequencing were used to analyze TBX1 promoter methylation. The biological functions of TBX1 in thyroid cancer cells were determined by a series of in vitro and in vivo experiments. Chromatin immunoprecipitation sequencing and dual-luciferase reporter assays were used to identify its downstream targets. Results: This study demonstrates that TBX1 is frequently downregulated by promoter methylation in both papillary thyroid cancers and thyroid cancer cell lines. Ectopic expression of TBX1 in thyroid cancer cells dramatically inhibits cell viability, colony formation, and tumorigenic potential in nude mice, and induces cell-cycle arrest and apoptosis through modulating a panel of cell-cycle and apoptosis-related genes. In addition, ectopic expression of TBX1 significantly decreases the migration and invasion potential of thyroid cancer cells through inhibiting the process of epithelial-mesenchymal transition and the expression of matrix metalloproteinases. On the other hand, TBX1 knockdown markedly promotes thyroid cancer cell viability and invasiveness. Mechanistically, TBX1 exerts its tumor suppressor function in thyroid cancer cells through inhibiting phosphorylation of AKT at Ser473 and ERK via regulating its downstream targets such as RNF41, PARK2, and PHLPP2. Conclusions: The data show that TBX1 is frequently inactivated by promoter methylation and functions as a potential tumor suppressor in thyroid cancer through inhibiting the activities of the PI3K/AKT and MAPK/ERK signaling pathways.

Thyroid Hormone Receptors as Tumor Suppressors in Cancer

Common tumor‐suppressive signaling of thyroid hormone receptor beta in breast and thyroid cancer cells

Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis

Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma*

Thyroid Hormone Receptor Β1 Suppresses Proliferation and Migration by Inhibiting PI3K/Akt Signaling in Human Colorectal Cancer Cells.

Thyroid hormone actions in liver cancer.

Thyroid hormone receptor α1: a novel regulator of thyroid cancer cell differentiation

Tumor Suppressor P53 is a Negative Regulator in Thyroid Hormone Receptor Signaling Pathways.

TR4 Nuclear Receptor Suppresses HCC Cell Invasion Via Downregulating the EphA2 Expression

Lack of Mutations in the Thyroid Hormone Receptor (TR) α and β Genes but Frequent Hypermethylation of the TRβ Gene in Differentiated Thyroid Tumors

Structural Insights Into Thyroid Hormone Receptors

Tbx1 Functions As A Tumor Suppressor In Thyroid Cancer Through Inhibiting The Activities Of The Pi3k/Akt And Mapk/Erk Pathways

Thyroid Hormone Receptor and Human Cancer

Targeting Tumor Suppressor Networks for Cancer Therapeutics

TRIM29 Promotes Progression of Thyroid Carcinoma Via Activating P13K/AKT Signaling Pathway.

Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors.

Physiological and Pathophysiological Roles of Ion Transporter-Mediated Metabolism in the Thyroid Gland and in Thyroid Cancer

An Integrative Analysis of the Tumor Suppressors and Oncogenes from Sexual Dimorphism and Gene Expression Alteration Features in Thyroid Cancer.

Targeting Tumor Suppressor Genes for Cancer Therapy

The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies

Novel Pathway for Thyroid Hormone Receptor Action Through Interaction with Jun and Fos Oncogene Activities.